IL238958B - Glutaminase inhibitors, preparations containing them and their uses - Google Patents

Glutaminase inhibitors, preparations containing them and their uses

Info

Publication number
IL238958B
IL238958B IL238958A IL23895815A IL238958B IL 238958 B IL238958 B IL 238958B IL 238958 A IL238958 A IL 238958A IL 23895815 A IL23895815 A IL 23895815A IL 238958 B IL238958 B IL 238958B
Authority
IL
Israel
Prior art keywords
compositions
same
glutaminase inhibitors
glutaminase
inhibitors
Prior art date
Application number
IL238958A
Other languages
English (en)
Hebrew (he)
Other versions
IL238958A0 (en
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of IL238958A0 publication Critical patent/IL238958A0/en
Publication of IL238958B publication Critical patent/IL238958B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL238958A 2012-11-22 2015-05-21 Glutaminase inhibitors, preparations containing them and their uses IL238958B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2012/085023 WO2014079011A1 (en) 2012-11-22 2012-11-22 Heterocyclic compounds for inhibiting glutaminase and their methods of use
PCT/CN2013/000294 WO2014079136A1 (en) 2012-11-22 2013-03-15 Compounds, pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof
PCT/CN2013/001428 WO2014079150A1 (en) 2012-11-22 2013-11-21 Compounds and their methods of use

Publications (2)

Publication Number Publication Date
IL238958A0 IL238958A0 (en) 2015-07-30
IL238958B true IL238958B (en) 2019-09-26

Family

ID=50775393

Family Applications (1)

Application Number Title Priority Date Filing Date
IL238958A IL238958B (en) 2012-11-22 2015-05-21 Glutaminase inhibitors, preparations containing them and their uses

Country Status (36)

Country Link
US (2) US10087172B2 (cg-RX-API-DMAC7.html)
EP (2) EP2922850B1 (cg-RX-API-DMAC7.html)
JP (2) JP6333277B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150085079A (cg-RX-API-DMAC7.html)
CN (2) CN108727307A (cg-RX-API-DMAC7.html)
AR (1) AR093598A1 (cg-RX-API-DMAC7.html)
AU (2) AU2013347771B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015011830A2 (cg-RX-API-DMAC7.html)
CA (1) CA2893510C (cg-RX-API-DMAC7.html)
CL (1) CL2015001392A1 (cg-RX-API-DMAC7.html)
CR (1) CR20150316A (cg-RX-API-DMAC7.html)
CY (1) CY1120581T1 (cg-RX-API-DMAC7.html)
DK (1) DK2922850T3 (cg-RX-API-DMAC7.html)
EA (2) EA030646B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP15026557A (cg-RX-API-DMAC7.html)
ES (1) ES2690390T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20181628T1 (cg-RX-API-DMAC7.html)
HU (1) HUE040111T2 (cg-RX-API-DMAC7.html)
IL (1) IL238958B (cg-RX-API-DMAC7.html)
LT (1) LT2922850T (cg-RX-API-DMAC7.html)
MX (1) MX367389B (cg-RX-API-DMAC7.html)
MY (1) MY177344A (cg-RX-API-DMAC7.html)
NZ (1) NZ708382A (cg-RX-API-DMAC7.html)
PE (1) PE20151072A1 (cg-RX-API-DMAC7.html)
PH (2) PH12015501150B1 (cg-RX-API-DMAC7.html)
PL (1) PL2922850T3 (cg-RX-API-DMAC7.html)
PT (1) PT2922850T (cg-RX-API-DMAC7.html)
RS (1) RS57859B1 (cg-RX-API-DMAC7.html)
SA (1) SA515360469B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201609940RA (cg-RX-API-DMAC7.html)
SI (1) SI2922850T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800504T1 (cg-RX-API-DMAC7.html)
TR (1) TR201812360T4 (cg-RX-API-DMAC7.html)
TW (2) TWI629268B (cg-RX-API-DMAC7.html)
UA (1) UA117360C2 (cg-RX-API-DMAC7.html)
WO (3) WO2014079011A1 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
US10793535B2 (en) 2012-11-16 2020-10-06 Calithera Biosciences, Inc. Heterocyclic glutaminase inhibitors
KR20150085078A (ko) 2012-11-21 2015-07-22 아지오스 파마슈티컬스 아이엔씨. 글루타마제 억제제 및 사용 방법
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
CN105283182A (zh) * 2012-12-03 2016-01-27 卡利泰拉生物科技公司 用谷氨酰胺酶的杂环抑制剂治疗癌症
CA2897200C (en) 2013-01-14 2021-07-06 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
AR094664A1 (es) 2013-01-15 2015-08-19 Incyte Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
CN105960405B (zh) * 2014-01-06 2021-02-19 理森制药股份公司 谷氨酰胺酶抑制剂
CA2943339A1 (en) * 2014-03-21 2015-09-24 Agios Pharmaceuticals, Inc. Compounds and their methods of use
PE20161436A1 (es) * 2014-04-30 2017-01-08 Pfizer Derivados de diheterociclo enlazado a cicloalquilo
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
PT3164394T (pt) 2014-07-03 2020-05-08 Univ Texas Inibidores gls1 para o tratamento de doenças
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016014890A1 (en) * 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
EP3193876B1 (en) 2014-08-07 2022-01-12 Calithera Biosciences Inc. Crystal forms of glutaminase inhibitors
US10245254B2 (en) 2014-10-03 2019-04-02 University of Pittsburgh—of the Commonwealth System of Higher Education Glutaminase inhibitors
KR20170132333A (ko) 2015-04-06 2017-12-01 칼리테라 바이오사이언시즈, 인코포레이티드 글루타미나제 억제제에 의한 폐암의 치료
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AU2016287661B2 (en) * 2015-06-30 2020-07-16 Board Of Regents, University Of Texas System GLS1 inhibitors for treating disease
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
AU2016335991A1 (en) 2015-10-05 2018-05-10 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
TW201731511A (zh) * 2015-11-30 2017-09-16 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
CN106890184B (zh) * 2015-12-18 2019-06-25 诺言医药科技(上海)有限公司 抗肿瘤的谷氨酰胺酶抑制剂和肿瘤血管生成抑制剂药物组合物及其应用
KR102777513B1 (ko) 2015-12-22 2025-03-06 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 (r)-1-(4-(6-(2-(4-(3,3-디플루오로시클로부톡시)-6-메틸피리딘-2-일)아세트아미도)피리다진-3-일)-2-플루오로부틸)-n-메틸-1h-1,2,3-트리아졸-4-카르복사미드의 염 형태 및 다형체
MX2019002108A (es) * 2016-08-25 2019-07-08 Calithera Biosciences Inc Terapia de combinacion con inhibidores de glutaminasa.
CN109982703A (zh) 2016-08-25 2019-07-05 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂的组合疗法
WO2019079632A1 (en) 2017-10-18 2019-04-25 Board Of Regents, The University Of Texas System GLUTAMINASE INHIBITOR THERAPY
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
US20210403479A1 (en) 2018-11-08 2021-12-30 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
US20220400732A1 (en) * 2019-03-21 2022-12-22 Cornell University Anti-fructose therapy for colorectal and small intestine cancers
CN110746416A (zh) * 2019-09-05 2020-02-04 中国药科大学 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途
CN112898200A (zh) * 2021-01-20 2021-06-04 都创(上海)医药科技股份有限公司 5-溴-6-甲氧基吡啶-2-羧酸酯的合成方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
US4070400A (en) 1975-10-16 1978-01-24 Merck & Co., Inc. Diphenyl polyamides having a cyclohexylene moiety
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
SU1761672A1 (ru) * 1990-05-22 1992-09-15 Белгородский технологический институт строительных материалов им.И.А.Гришманова Способ получени тонкодисперсного мела
JPH08508270A (ja) 1993-03-29 1996-09-03 ビーエーエスエフ アクチエンゲゼルシャフト マルチ・ドラッグ耐性のモジュレーターとしての1−アミノ−3−フェノキシ−プロパン誘導体
US5895748A (en) 1996-11-27 1999-04-20 Johnson; Keith R. Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies
DE69923681T2 (de) 1998-06-18 2006-01-12 Bristol-Myers Squibb Co. Kohlenstoff substituierte aminothiazole als inhibitoren von cyclin-abhängigen kinasen
EP1388734B1 (en) 2002-08-01 2004-03-03 MTM Laboratories AG Method for solution based diagnosis
US6335170B1 (en) 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors
WO2001062206A2 (en) 2000-02-22 2001-08-30 Mount Sinai School Of Medicine Of New York University N-cadherin modulated migration, invasion, and metastasis
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US6451828B1 (en) * 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
US20080182865A1 (en) 2005-03-11 2008-07-31 Witta Samir E Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
CA2601157A1 (en) 2005-03-16 2006-09-28 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US8716472B2 (en) 2006-10-16 2014-05-06 University Of Rochester Tripodal cyclohexane derivatives and their use as carbohydrate receptors
EP2220123A1 (en) 2007-11-19 2010-08-25 Genentech, Inc. Compositions and methods for inhibiting tumor progression
EP2271941B1 (en) 2008-03-07 2012-08-08 OSI Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP3021120A1 (en) 2009-02-20 2016-05-18 Michael P. Lisanti Diagnosis, prognosis, therapeutics and methods for treating neoplastic deiseases comprising determining the level of caveolin-1 in a stromal cell sample
WO2010111504A2 (en) 2009-03-25 2010-09-30 Cornell University Inhibition of glutaminase c
EP2419177A1 (en) 2009-04-17 2012-02-22 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
US20130109643A1 (en) * 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
WO2011163332A2 (en) 2010-06-23 2011-12-29 University Of Louisville Research Foundation, Inc. Methods for detecting cancer
WO2012006506A1 (en) * 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
SG11201402305WA (en) * 2011-11-21 2014-06-27 Calithera Biosciences Inc Heterocyclic inhibitors of glutaminase
US20150037354A1 (en) 2012-03-15 2015-02-05 The Resesrch Foundation for The State University of New York Combination therapies including inhibitors of the extracellular domain of e-cadherin
KR20150085078A (ko) 2012-11-21 2015-07-22 아지오스 파마슈티컬스 아이엔씨. 글루타마제 억제제 및 사용 방법
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
US20160008380A1 (en) 2013-03-06 2016-01-14 The Johns Hopkins University Targeting glutamine metabolism in brain tumors
CN105960405B (zh) 2014-01-06 2021-02-19 理森制药股份公司 谷氨酰胺酶抑制剂
CA2943339A1 (en) 2014-03-21 2015-09-24 Agios Pharmaceuticals, Inc. Compounds and their methods of use

Also Published As

Publication number Publication date
EP2922850A1 (en) 2015-09-30
SI2922850T1 (sl) 2018-10-30
EP2922850A4 (en) 2016-05-18
UA117360C2 (uk) 2018-07-25
US20150291576A1 (en) 2015-10-15
HK1214593A1 (en) 2016-07-29
US10087172B2 (en) 2018-10-02
EP2922850B1 (en) 2018-07-18
KR20150085079A (ko) 2015-07-22
MX2015006493A (es) 2015-08-05
CR20150316A (es) 2015-08-28
PE20151072A1 (es) 2015-08-26
PL2922850T3 (pl) 2018-12-31
WO2014079150A1 (en) 2014-05-30
TR201812360T4 (tr) 2018-09-21
CN108727307A (zh) 2018-11-02
NZ708382A (en) 2020-04-24
CA2893510A1 (en) 2014-05-30
ES2690390T3 (es) 2018-11-20
AU2013347771A1 (en) 2015-06-11
PH12015501150B1 (en) 2018-05-04
HUE040111T2 (hu) 2019-02-28
TW201427963A (zh) 2014-07-16
EP3456719A1 (en) 2019-03-20
CN104936954B (zh) 2018-08-14
ECSP15026557A (es) 2016-01-29
CN104936954A (zh) 2015-09-23
PH12017502141A1 (en) 2019-02-27
IL238958A0 (en) 2015-07-30
EA201890754A1 (ru) 2018-08-31
SG10201609940RA (en) 2016-12-29
RS57859B1 (sr) 2018-12-31
WO2014079011A1 (en) 2014-05-30
EA201590987A1 (ru) 2015-12-30
DK2922850T3 (en) 2018-10-08
CA2893510C (en) 2021-01-19
CL2015001392A1 (es) 2016-04-22
WO2014079136A1 (en) 2014-05-30
CY1120581T1 (el) 2019-07-10
LT2922850T (lt) 2018-09-10
JP2018150316A (ja) 2018-09-27
PT2922850T (pt) 2018-10-15
SA515360469B1 (ar) 2017-07-11
US20190084976A1 (en) 2019-03-21
TWI629268B (zh) 2018-07-11
BR112015011830A2 (pt) 2017-07-11
MX367389B (es) 2019-08-19
TW201906825A (zh) 2019-02-16
AU2013347771B2 (en) 2018-02-01
SG11201504049VA (en) 2015-07-30
EA030646B1 (ru) 2018-09-28
PH12015501150A1 (en) 2015-08-17
MY177344A (en) 2020-09-13
JP2016500082A (ja) 2016-01-07
US10689375B2 (en) 2020-06-23
HRP20181628T1 (hr) 2018-12-14
AU2018202954A1 (en) 2018-05-17
JP6333277B2 (ja) 2018-05-30
AR093598A1 (es) 2015-06-10
SMT201800504T1 (it) 2018-11-09

Similar Documents

Publication Publication Date Title
IL238958B (en) Glutaminase inhibitors, preparations containing them and their uses
IL238959A (en) Glutamase suppressors, preparations containing them and their uses
IL261436B (en) Preparations containing masp-2 suppressors and their uses
IL252063A0 (en) dna-pk suppressors, preparations containing them and their uses
IL240196B (en) Amide compounds, preparations containing them and their uses
IL233503A0 (en) Isocitrate dehydrogenase inhibitors, preparations containing them and their uses
IL246061A0 (en) Prodrugs of pyridone amide, preparations containing them and their uses
IL235155B (en) Arginase inhibitor compounds, compositions comprising same and uses thereof
IL241330A0 (en) pk - dna suppressor compounds, preparations containing them and their uses
IL269964A (en) Pyridone amide compounds, compositions containing them and uses thereof
HUE044300T2 (hu) 3-amino-cikloalkil-vegyületek, mint ROR-GAMMA-T inhibitorok és alkalmazásuk
IL234014A (en) Cycloalkane derivatives, preparations containing them and their uses
IL237625A0 (en) Antibodies against m-cam, preparations containing them and their uses
EP2802330A4 (en) IRAQ INHIBITORS AND USES THEREOF
EP2872518A4 (en) IRAQ INHIBITOR AND USES THEREOF
IL235585A0 (en) Substances that bind to ha, preparations containing them and their uses
IL235004A0 (en) Antibodies against fgfr2, preparations containing them and their uses
IL241355B (en) Pyrazole-amide compounds, preparations containing them and their uses
IL234884A0 (en) Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
IL233824A (en) Compounds 1h - Indazole - 3 - Carboxamide, preparations containing them and their use
IL236712A0 (en) Di-teri-heteroaryl derivatives, preparations containing them and their uses
IL237542B (en) Amphiphilic compounds, their preparations and uses
EP2874641A4 (en) COMPOSITIONS INCREASING THE GLUTATHION RATE AND USES THEREOF
IL233682A0 (en) Modified phenylazole derivatives, preparations containing them and their uses
IL267888B (en) Amphiphilic compounds, their preparations and uses

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees